Celcuity Inc. (NASDAQ:CELC) Shares Sold by BNP Paribas Financial Markets

BNP Paribas Financial Markets reduced its holdings in Celcuity Inc. (NASDAQ:CELC) by 92.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,325 shares of the company’s stock after selling 41,785 shares during the quarter. BNP Paribas Financial Markets’ holdings in Celcuity were worth $44,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in the business. Ameriprise Financial Inc. increased its stake in Celcuity by 45.9% in the fourth quarter. Ameriprise Financial Inc. now owns 447,171 shares of the company’s stock valued at $5,853,000 after purchasing an additional 140,642 shares during the last quarter. Northern Trust Corp increased its stake in Celcuity by 16.4% in the fourth quarter. Northern Trust Corp now owns 300,076 shares of the company’s stock valued at $3,928,000 after purchasing an additional 42,186 shares during the last quarter. The Manufacturers Life Insurance Company acquired a new position in Celcuity in the fourth quarter valued at $142,000. Aquatic Capital Management LLC acquired a new position in Celcuity in the fourth quarter valued at $50,000. Finally, Price T Rowe Associates Inc. MD acquired a new stake in Celcuity during the fourth quarter worth about $167,000. 63.33% of the stock is currently owned by institutional investors and hedge funds.

Celcuity Stock Performance

Shares of NASDAQ:CELC opened at $11.94 on Wednesday. Celcuity Inc. has a 12 month low of $7.58 and a 12 month high of $19.77. The business has a 50-day moving average of $10.24 and a two-hundred day moving average of $11.31. The company has a debt-to-equity ratio of 0.65, a current ratio of 10.35 and a quick ratio of 10.36. The firm has a market capitalization of $452.12 million, a PE ratio of -4.57 and a beta of 0.56.

Celcuity (NASDAQ:CELC) last issued its earnings results on Wednesday, May 14th. The company reported ($0.86) earnings per share for the quarter, topping the consensus estimate of ($0.95) by $0.09. As a group, research analysts forecast that Celcuity Inc. will post -2.62 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have commented on CELC. HC Wainwright restated a “buy” rating and set a $27.00 price target on shares of Celcuity in a research note on Monday, May 19th. Needham & Company LLC restated a “buy” rating and set a $29.00 price target on shares of Celcuity in a research note on Thursday, May 15th. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $30.80.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.